ObjectiveIdiopathic subglottic stenosis (iSGS) is a progressive fibrotic condition of the subglottis that presents in women of northern European descent. Endoscopic dilation is a common surgical approach to management of iSGS. The surgery‐free interval, or the time between endoscopic dilation procedures is considered an indicator of disease severity. Variations in surgery‐free intervals among iSGS patients underscore the necessity for prognostic biomarkers. The objective of this study was to explore serum levels of the damage‐associated molecular pattern S100A8/A9 as a prognostic biomarker in iSGS.MethodsSerum from 20 iSGS patients and eight healthy controls was collected and S100A8/A9 levels were quantified using an ELISA. Patient data, including demographics and surgery‐free intervals, were obtained from medical records. Serum S100A8/A9 levels were compared to surgery‐free intervals. S100A8/A9 was also assessed using gene expression and immunofluorescence in iSGS specimens.ResultsS100A8/A9 was significantly elevated (p = 0.0413) in the serum of iSGS patients compared to controls (312.75 vs. 181.49 ng/mL). Linear regression analysis revealed a correlation (p = 0.009) between S100A8/A9 levels and endoscopic surgery‐free interval. S100A8/A9 was significantly elevated (p = 0.0011) in patients with surgery‐free intervals less than 1 year (455.2 ± 60.45 ng/mL; n = 8) compared to patients with intervals over 1 year (292.5.93 ± 162.4; n = 6).ConclusionS100A8/A9 is increased in the serum and tissue of patients with iSGS. In this cohort of iSGS patients, serum S100A8/A9 was associated with surgery‐free intervals, potentially representing a prognostic biomarker. Further research within a larger cohort is needed to confirm these findings.Level of EvidenceLevel 3 Laryngoscope, 2024